| Bagel, Jerry |
NCT06745999: Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face |
|
|
| Recruiting | 4 | 40 | US | Ameluz 10% Topical Gel, ALA gel, Red Light PDT, Cryotherapy | Psoriasis Treatment Center of Central New Jersey, Biofrontera Bioscience GmbH | Actinic Keratoses | 05/25 | 06/25 | | |
NCT05285839: Dupixent and Narrowband UVB for Atopic Dermatitis |
|
|
| Recruiting | 4 | 40 | US | Dupixent | Psoriasis Treatment Center of Central New Jersey, Regeneron Pharmaceuticals | Atopic Dermatitis | 12/24 | 12/24 | | |
| Recruiting | 4 | 25 | US | Upadacitinib | Psoriasis Treatment Center of Central New Jersey, AbbVie | Prurigo Nodularis | 12/25 | 01/26 | | |
| Recruiting | 4 | 60 | US | Bimekizumab | Icahn School of Medicine at Mount Sinai, UCB Pharma, Psoriasis Treatment Center of Central New Jersey | Plaque Psoriasis | 10/25 | 10/25 | | |
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab |
|
|
| Active, not recruiting | 3 | 120 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 01/24 | 02/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 75 | US | LY3972406, Placebo | Eli Lilly and Company | Plaque Psoriasis | 04/25 | 07/25 | | |
| Completed | N/A | 783 | US | Daavlin 7 series 3 panel narrow band phototherapy home units, narrow band phototherapy clinic units | University of Pennsylvania, University of Utah, National Psoriasis Foundation, Patient-Centered Outcomes Research Institute | Psoriasis, Psoriatic Plaque | 10/23 | 12/23 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Nieves, David Sánchez |
NCT06745999: Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face |
|
|
| Recruiting | 4 | 40 | US | Ameluz 10% Topical Gel, ALA gel, Red Light PDT, Cryotherapy | Psoriasis Treatment Center of Central New Jersey, Biofrontera Bioscience GmbH | Actinic Keratoses | 05/25 | 06/25 | | |
| Recruiting | 4 | 25 | US | Upadacitinib | Psoriasis Treatment Center of Central New Jersey, AbbVie | Prurigo Nodularis | 12/25 | 01/26 | | |
| Chapman, Michael S |
NCT04223570: Portable Measurement of Protoporphyrin IX in the Skin |
|
|
| Enrolling by invitation | N/A | 218 | US | Portable Apple Smart Phone Protoporphyrin IX Spectrometer Camera | Dartmouth-Hitchcock Medical Center | Photodynamic Therapy, Protoporphyrin IX | 03/25 | 03/25 | | |
BRITISH, NCT05568069: RCT of Implantable Defibrillators in Patients with Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure |
|
|
| Recruiting | N/A | 2504 | Europe | Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronisation Therapy Defibrillator (CRTD) | University Hospital Southampton NHS Foundation Trust, British Heart Foundation, University of Southampton | Heart Failure | 04/26 | 04/36 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Thornblade, Carl |
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma |
|
|
| Recruiting | 3 | 292 | US, RoW | FF/UMEC/VI, ELLIPTA, FF/VI | GlaxoSmithKline | Asthma | 01/27 | 01/27 | | |
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Recruiting | 2 | 154 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 06/25 | 07/25 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Nelson, Elise |
NCT05285839: Dupixent and Narrowband UVB for Atopic Dermatitis |
|
|
| Recruiting | 4 | 40 | US | Dupixent | Psoriasis Treatment Center of Central New Jersey, Regeneron Pharmaceuticals | Atopic Dermatitis | 12/24 | 12/24 | | |
| Recruiting | 4 | 60 | US | Bimekizumab | Icahn School of Medicine at Mount Sinai, UCB Pharma, Psoriasis Treatment Center of Central New Jersey | Plaque Psoriasis | 10/25 | 10/25 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Yu, Henry |
NCT04987112: Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors |
|
|
| Recruiting | 1 | 36 | US | CAN1012 | CanWell Pharma Inc. | Solid Tumor, Cancer Metastatic | 12/24 | 12/24 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
